Now, companies like Proteus Digital Health are working towards developing smart pills, drugs with tiny sensors inside, which can track medication adherence. Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday. Our evidence suggests that these applications show great promise to transform patient care and enable contracting for expensive therapies that tie payments to actual use of [the] drug.”Studies into hepatitis C, tuberculosis and cardiometabolic syndrome have been able to demonstrate strong clinical outcomes for digital medicines in these areas as well as high degrees of patient satisfaction.
Proteus’ ingestible sensors transmit a signal to a patch worn on the torso once they reach the stomach, sending a digital record to a patient’s mobile phone. This adoption, as we know, relies on more than just the technical capabilities of transmitting an electronic signal from the body to a receiver indicating adherence. "They may be paying the price for that tactical choice, because it’s such a challenging therapeutic modality for their particular intervention to take hold. Proteus Digital Health valuation is $1.6 b,. The ingestible sensor is part of the digital health feedback system, which includes a wearable sensor and secure app and is largely focused on serving the transplant population and patients with chronic illnesses. With permission, doctors and caregivers can then monitor whether or not medication has been taken properly remotely via the Proteus cloud.In theory, smart pills like these will not only help patients track if they’ve taken their medication properly, but will help them collaborate with their physician to manage their treatment. The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment. Company status Active Company type Private limited Company Incorporated on 29 … Bill Evans, managing director of digital health venture fund and research group Rock Health, “Proteus may have picked [a] therapeutic area with a degree of difficulty that’s an eight or nine out of 10, right?" Proteus’ ingestible sensors transmit a signal to a patch worn on the torso once they reach the stomach, sending a digital record to a patient’s mobile phone. Evans said at the time. Still, there are several examples of ingestible sensor technology already out in the wild.Through Otsuka, Abilify MyCite had been, or already was, rolled out among providers for studies and pilots involving The latest news in digital health delivered daily to your inbox.© 2020 MobiHealthNews is a publication of HIMSS MediaThe latest news in digital health delivered daily to your inbox.The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its ingestible-sensor business. Lawrence Perkins of SierraConstellation Partners, who had previously been retained as the company's chief restructuring officer, has now been appointed by the Proteus board as its interim CEO.“Filing for bankruptcy protection allows Proteus to continue its sales process in a more concerted and efficient manner while continuing to run the business as usual,” the company said in a statement provided to A representative from Otsuka said that the company won't be putting out any official statement on its business partner's bankruptcy, but said that delivery of Abilify MyCite – a sensor-enabled version of Otsuka's schizophrenia drug that was developed as a result of the companies' collaboration – will not be affected. But I suspect in the mental health market it was always a bit of an uphill struggle, since this is a massive change in the treatment of psychoses.”For better or for worse, patients with cancer or infectious diseases tend to be monitored far more closely by their primary care teams than people with schizophrenia, and have more complex medication regimens. Also known as aripiprazole, Abilify is an antipsychotic used to treat schizophrenia, bipolar disorder and depression.“Otsuka Pharmaceutical and Proteus Digital Health have signed a contract amendment and revised agreement that provides Otsuka with Proteus’ ingestible and wearable sensor technology for use in the development of Otsuka’s digital medicine product portfolio,” an Otsuka Pharmaceutical representative says. It requires a value proposition or technology-enabled service set up around the smart pill for all stakeholders involved so that it is prescribed, taken, and the data used in a way that clearly demonstrates value to the users.”Data alone is not sufficient to change a patient’s behaviour.Even the most motivated patients often forget to take their medication. Now, companies like Proteus Digital Health are working towards developing smart pills, drugs with tiny sensors inside, which can track medication adherence.